Several studies have shown that SGLT2i are associated with favourable CV and renal outcomes, by reducing the risks of death from CV causes, myocardial infarction, ischaemic stroke, HF hospitalizations, reduced renal function, end-stage renal disease, or death from renal causes, regardless of glucose control.1–4 This consistent evidence supports an early use of these drugs in patients with type 2 diabetes and high or very-high CV risk
The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending / Volpe, Massimo; Patrono, Carlo. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - 42:15(2021), pp. 1458-1459. [10.1093/eurheartj/ehab136]
The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending
Volpe, Massimo;Patrono, Carlo
2021
Abstract
Several studies have shown that SGLT2i are associated with favourable CV and renal outcomes, by reducing the risks of death from CV causes, myocardial infarction, ischaemic stroke, HF hospitalizations, reduced renal function, end-stage renal disease, or death from renal causes, regardless of glucose control.1–4 This consistent evidence supports an early use of these drugs in patients with type 2 diabetes and high or very-high CV risk| File | Dimensione | Formato | |
|---|---|---|---|
|
Volpe_The-value_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
246.51 kB
Formato
Adobe PDF
|
246.51 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
